Original articleIngenol mebutate gel for actinic keratosis: The link between quality of life, treatment satisfaction, and clinical outcomes
Section snippets
Patient population
Patients were aged 18 years or older and had 4 to 8 clinically typical, visible, discrete AKs within a contiguous 25-cm2 area on the face, scalp, trunk, or extremities. Inclusion and exclusion criteria have been published previously.18 Participating center ethical review boards approved each study, and patients provided written informed consent and allowed photographs of the selected treatment area to be taken.
Trial designs
Four phase-III multicenter, randomized, double-blind, vehicle-controlled trials were
Patient characteristics
Overall, 1005 patients were randomized (ingenol mebutate n = 277 and vehicle n = 270 for face/scalp; ingenol mebutate n = 226 and vehicle n = 232 for trunk/extremities). Patient baseline characteristics and disposition have been reported previously.18
TSQM/Skindex-16 results
Overall, completion rates were high (91.6%-98.9%) for both questionnaires. Patients treated with ingenol mebutate in the face/scalp group and the trunk/extremities group reported significantly greater satisfaction with effectiveness and global
Discussion
Ingenol mebutate therapy significantly improved QoL and treatment satisfaction in phase-III trials. Improvements from baseline were greatest for the emotions domain in Skindex-16. Greater improvements were reported in the face/scalp than for the trunk/extremities group for the emotions and symptoms domains, which reflect the higher efficacy rates for ingenol mebutate on the face/scalp compared with other locations. The results confirm reports of treatment-related improvements in QoL in patients
References (28)
- et al.
Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness
J Invest Dermatol
(1996) - et al.
Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response
J Am Acad Dermatol
(2012) - et al.
Clinical findings using ingenol mebutate gel to treat actinic keratoses
J Am Acad Dermatol
(2013) - et al.
Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis
J Am Acad Dermatol
(2009) - et al.
Quality of life in the actinic neoplasia syndrome: the VA topical tretinoin chemoprevention (VATTC) trial
J Am Acad Dermatol
(2009) - et al.
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
J Am Acad Dermatol
(2004) - et al.
Review of actinic keratosis, part I: etiology, epidemiology and clinical presentation
J Drugs Dermatol
(2010) - et al.
Actinic keratoses: past, present and future
J Drugs Dermatol
(2010) - et al.
Guidelines for the management of actinic keratoses
Br J Dermatol
(2007) - et al.
Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs topical tretinoin chemoprevention trial
Cancer
(2009)
Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer
J Clin Aesthet Dermatol
Topical zinc sulphate (25%) solution: a new therapy for actinic keratosis
J Cutan Aesthet Surg
Management of field change in actinic keratosis
Br J Dermatol
Management of actinic keratosis patients: a qualitative study
J Dermatolog Treat
Cited by (34)
Quality of Life, Behaviour and Attitudes towards Actinic Keratosis in Spain: The PIQA Study
2018, Actas Dermo-SifiliograficasPain during topical photodynamic therapy - comparing methyl aminolevulinate (Metvix<sup>®</sup>) to aminolaevulinic acid (Ameluz<sup>®</sup>); an intra-individual clinical study
2017, Photodiagnosis and Photodynamic TherapyCitation Excerpt :Actinic keratoses (AKs) are the most common pre-malignancies of the skin. They cause disfigurement, pain and loss of quality of life [1–5]. If left untreated they may evolve into squamous cell carcinoma and is therefore most often treated [6].
Treatment Satisfaction and Acceptability of 20% Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses of the Face, Scalp, and Upper Extremities
2023, Journal of Clinical and Aesthetic DermatologyPatient-reported outcomes of topical therapies in actinic keratosis: A systematic review
2021, Dermatologic TherapySafety of topical interventions for the treatment of actinic keratosis
2021, Expert Opinion on Drug Safety
These studies (PEP005-014; PEP005-016; PEP005-025; PEP005-028) were funded by Peplin Operations Pty Ltd (subsequently acquired by LEO Pharma A/S).
Disclosure: Dr Augustin has served as a consultant and investigator for LEO Pharma A/S and Almirall. Dr Tu reports industry relationships with TOLMAR, Photocure, Graceway Pharmaceuticals, Apotex, Nycomed Pharma, and Teva Pharmaceutical Industries. Drs Knudsen, Erntoft, and Larsson are employees of LEO Pharma A/S. Dr Hanke reports industry relationships with Allergan, Dermik, Educational Testing and Assessment Systems, Eli Lilly, Elsevier, Galderma, Informa, Kythera, LEO Pharma A/S, Merz Pharma, Orlando Dermatology Aesthetic and Clinical, Sanova Dermatology, and Springer.
Some of these data have been presented previously:
- •
Berman B, Marmur E, Melgaard A. Three-day topical treatment with ingenol mebutate gel 0.015% for actinic keratoses on the face and scalp: analysis of data pooled from 2 trials. Poster P5623 presented at the Annual Meeting of the American Academy of Dermatology; San Diego, CA; March 16-20, 2012.
- •
Anderson LL, Schmeider GJ, Xu Z, Melgaard A. Two-day topical treatment with ingenol mebutate gel 0.05% for actinic keratoses on the trunk and extremities: analysis of data pooled from 2 trials. Poster P5640 presented at the Annual Meeting of the American Academy of Dermatology; San Diego, CA; March 16-20, 2012.
- •
Augustin M, Tu JH, Knudsen KM, Erntoft S, Larsson T, Hanke W. Effect of ingenol mebutate gel on treatment satisfaction and quality of life in actinic keratosis. E-poster P1645 (IST13-1530) presented at the 22nd Congress of the European Academy of Dermatology and Venereology; Istanbul, Turkey; October 3-6, 2013.
- •